PDF herunterladen
Geburtshilfe Frauenheilkd 2003; 63(12): 1233-1245
DOI: 10.1055/s-2003-44644
Übersicht

Georg Thieme Verlag Stuttgart · New York

Villöse und nicht villöse gestationsbedingte Trophoblasterkrankungen - eine Übersicht

Gestational Trophoblastic Disease - a ReviewL.-C. Horn 1 , M. Vogel 2 , K. Bilek 3 , J. Einenkel 3
  • 1Institut für Pathologie, Gynäkopathologie, Universität Leipzig
  • 2Institut für Pathologie, Abteilung für Paidopathologie und Placentologie, Humboldt Universität zu Berlin, Charité
  • 3Universitätsfrauenklinik Leipzig (Triersches Institut)
Weitere Informationen

Publikationsverlauf

Eingang Manuskript: 23. Oktober 2002 Eingang revidiertes Manuskript: 5. März 2003

Akzeptiert: 12. März 2003

Publikationsdatum:
26. November 2003 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Gestationsbedingte Trophoblasterkrankungen (GTD) sind selten und stellen aufgrund ihrer klinikopathologischen Besonderheiten eine große Herausforderung für Pathologen und Kliniker dar. Die Blasenmole und die Partialmole als Formen der villösen GTD sind aufgrund ihres differenten Risikos für eine persistierende Erkrankung und ihres zytogenetischen Hintergrundes streng zu trennen. Die häufigste Form der nicht villösen GTD ist das Chorionkarzinom. Die notwendige Chemotherapie erfolgt in strenger Korrelation zum WHO-Prognosescore. Als weitere Entitäten sind in den vergangenen Jahren der Plazentabettknoten und die hyperplastische Implantationsstelle abgegrenzt worden, die keiner weiteren Therapie bedürfen und im Allgemeinen Zufallsbefunde darstellen. Zu den Tumoren, die vom intermediären Trophoblasten ausgehen, zählen der Plazentabetttumor und der jüngst beschriebene epitheloide Trophoblasttumor. Beide zeigen in der Majorität einen benignen Verlauf, sollten jedoch, ähnlich wie die Blasenmole und das Chorionkarzinom, mit sequenziellen HCG-Bestimmungen überwacht werden. Die Prognose der GTD hängt in entscheidendem Maße vom rechtzeitigen Beginn der adäquaten Therapie ab, was einer engen Kooperation zwischen Pathologen und Gynäkologen bedarf. Angestrebt werden sollte die Zentralisation der betroffenen Patientinnen in spezialisierten Einrichtungen.

Abstract

Gestational trophoblastic disease (GTD) comprises a spectrum of uncommon and unique clinical and pathologic entities. The process of GTD is now better understood and new entities such as placental-site trophoblastic tumor (PSST) and epitheloid trophoblastic tumor have been morphologically defined. Complete hydatiform mole, a form of the villous type of GTD, has to be distinguished from partial mole because of the different cytogenetic composition and risk for persistent disease. Choriocarcinoma is the most frequent form of nonvillous GTD. Both PSST and epitheloid trophoblastic tumor derive from the intermediate trophoblastic cells and usually have a benign course. Optimal treatment requires a precise morphologic classification and close cooperation between the pathologist and the clinician. All patients treated for GTD require long-term monitoring of serum hCG. Patients with GTD should be registered, and possibly treated, at specialized centers.

Schlüsselwörter

Chorionkarzinom - hyperplastische Implantationsstelle - Plazentabetttumor - Trophoblast - maligne - Trophoblasterkrankung - Schwangerschaft - gestationsbedingt

Key words

Trophoblast - gestational - trophoblastic disease - placental site trophoblastic tumor - placental site nodule - epitheloid trophoblastic tumor - choriocarcinoma - malignant - treatment - placenta

Literatur

  • 1 Baergen R N. Gestational choriocarcinoma.  Gen Diagn Pathol. 1997;  143 127-141
    PubMedGoogle Scholar
  • 2 Baergen R N, Rutgers J L. Trophoblastic lesions of the placental site.  Gen Diagn Pathol. 1997;  143 143-158
    PubMedGoogle Scholar
  • 3 Bagshawe K D. Risk and prognostic factors in trophoblastic neoplasia.  Cancer. 1976;  38 1173-1235
    PubMedGoogle Scholar
  • 4 Bagshawe K D, Dent J, Newlands E S, Begent R H, Rustin G J. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumors.  Brit J Obstet Gynaecol. 1989;  96 795-802
    PubMedGoogle Scholar
  • 5 Berkowitz R S, Goldstein D P. Gestational trophoblastic disease.  Cancer. 1995;  76: (Suppl 10) 2079-2085
    PubMedGoogle Scholar
  • 6 Bilek K, Horn L C, Abu Hmeidan F, Pretzsch G. Gestationsbedingte Trophoblasterkrankungen - Ergebnisse der Jahre 1976 - 1992.  Geburtsh Frauenheilk. 1994;  54 519-523
    PubMedGoogle Scholar
  • 7 Bischoff P, Martelli M. Current topic: Proteolysis in the penetration phase of the implantation process.  Placenta. 1992;  13 17-24
    PubMedGoogle Scholar
  • 8 Bower M, Paradinas F J, Fisher R A, Nicholson S K, Rustin G J, Begent R H, Bagshawe K D, Newlands E S. Placental site trophoblastic tumor: Molecular analysis and clinical experience.  Clin Cancer Res. 1996;  2 897-902
    PubMedGoogle Scholar
  • 9 Brackertz M. Zur Genetik der Blasenmolen.  Geburtsh Frauenheilk. 1983;  43 461-468
    PubMedGoogle Scholar
  • 10 Chang Y L, Chang T C, Hsueh S. Prognostic factors and treatment for placental site trophoblastic tumor: Report of 3 cases and analysis of 88 cases.  Gynecol Oncol. 1999;  73 216-222
    CrossrefPubMedGoogle Scholar
  • 11 Cheung A N, Shen D H, Khoo U S, Chiu M P, Tim V P, Chung L P, Ngan Ny. Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: Correlation with mdm2, proliferation index and clinicopathologic parameters.  Int J Gynecol Cancer. 1999;  9 123-130
    CrossrefPubMedGoogle Scholar
  • 12 Davis G A, Survit E A, Garay J P, Fortier J J. Sex assignment in gestational trophoblastic neoplasia.  Am J Obstet Gynecol. 1984;  148 722-725
    PubMedGoogle Scholar
  • 13 Denny L A, Dehaeck K, Nevin J, Soeters R, van Wuk A L, Megevand E, Block B. Placental site trophoblastic tumor: Three case reports and literature review.  Gynecol Oncol. 1995;  59 300-303
    CrossrefPubMedGoogle Scholar
  • 14 DiCintio E, Parazzini F, Rosa C, Chatenoud L, Benzi G. The epidemiology of gestational trophoblastic disease.  Gen Diagn Pathol. 1997;  143 103-108
    PubMedGoogle Scholar
  • 15 Dobson L S, Lorigan P C, Coleman R E, Hancock B W. Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide and dactinomycine) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycine) as second-line therapy for low risk disease.  Brit J Cancer. 2000;  82 1547-1552
    PubMedGoogle Scholar
  • 16 Faulk W P, Coulam C B, McIntyre J A. The role of trophoblast antigens in repetitive spontaneous abortions.  Semin Reprod Immunol. 1989;  7 180-187
    PubMedGoogle Scholar
  • 17 Fine C, Bundy A L, Berkowitz R S. Sonographic diagnosis of partial hydatidiform mole.  Obstet Gynecol. 1989;  73 414-420
    PubMedGoogle Scholar
  • 18 Fisher R A, Khatoon R, Paradinas F J, Roberts A P, Newlands E S. Repetitive complete hydatidiform mole can be biparental in origin and either male or female.  Hum Reprod. 2000;  15 594-598
    CrossrefPubMedGoogle Scholar
  • 19 Florio P, Severi F M, Cobellis L, Danero S, Bomé A, Luisi S, Petraglia F. Serum activin A and inhibin A. New clinical markers for hydatidiform mole.  Cancer. 2002;  94 2618-2622
    CrossrefPubMedGoogle Scholar
  • 20 Fox H, Laurini R N. Intraplacental choriocarcinoma: A report of two cases.  J Clin Pathol. 1988;  41 1085-1088
    PubMedGoogle Scholar
  • 21 Fox H. Differential diagnosis of hydatidiform mole.  Gen Diagn Pathol. 1997;  143 117-125
    PubMedGoogle Scholar
  • 22 Fulop V, Mok S C, Gati I, Berowitz R S. Recent advances in molecular biology of gestational trophoblastic disease. A review.  J Reprod Med. 2002;  47 369-379
    PubMedGoogle Scholar
  • 23 Genest D R. Partial hydatidiform mole: Clinicopathologic features, differential diagnosis, ploidy and molecular studies and gold standards for diagnosis.  Int J Gynecol Pathol. 2001;  20 315-322
    PubMedGoogle Scholar
  • 24 Goldstein D P, Berkowitz R S. Current management of complete and partial molar pregnancy.  J Reprod Med. 1994;  39 139-146
    PubMedGoogle Scholar
  • 25 Hamazaki S, Nakamoto S, Okino T. Epitheloid trophoblastic tumor: Morphological and immunohistochemical study of three lesions.  Hum Pathol. 1999;  30 1321-1327
    CrossrefPubMedGoogle Scholar
  • 26 Hammond C B, Borchert L G, Tyrey L. Treatment of metastatic trophoblastic disease: Good and poor prognosis.  Am J Obstet Gynecol. 1973;  115 451-457
    PubMedGoogle Scholar
  • 27 Herbst H, Horn L C, Löning T. Trophoblasterkrankungen und Trophoblasttumoren.  Pathologe. 1999;  20 72-81
    CrossrefPubMedGoogle Scholar
  • 28 Horn L C, Bilek K, Nenning H. Postpartal gestational choriocarcinoma initially misdiagnosed as squamous cell cancer of the uterine cervix.  Gen Diagn Pathol. 1997;  143 191-196
    PubMedGoogle Scholar
  • 29 Horn L C, Bilek K, Pretzsch G, Baier D. Chorionkarzinom bei tubarer Extrauteringravidität.  Geburtsh Frauenheilk. 1994;  54 375-377
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 30 Horn L C, Bilek K. Histologic classification and staging of gestational trophoblastic disease.  Gen Diagn Pathol. 1997;  143 87-101
    PubMedGoogle Scholar
  • 31 Horn L C, Emmrich P, Bilek K, Bruder E. Der frühe plazentare Trophoblast: II. Tumorförmige Störungen der trophoblastären Entwicklung.  Zentralbl Gynäkol. 1996;  118 591-597
    PubMedGoogle Scholar
  • 32 Horn L C, Rosenkranz M, Bilek K. Wertigkeit der Plazentahistologie für die Erkennung genetisch bedingter Aborte.  Z Geburtsh Perinatol. 1991;  195 47-53
    PubMedGoogle Scholar
  • 33 Horn L C. Genetisch bedingte Frühaborte.  Gynäkol Prax. 1993;  17 21-32
    PubMedGoogle Scholar
  • 34 Huettner P C, Gersell D J. Placental site nodule: A clinicopathologic study of 38 cases.  Int J Gynecol Pathol. 1994;  13 191-198
    PubMedGoogle Scholar
  • 35 Janni W, Hantschmann P, Rehbock J, Braun S, Locmüller E, Kindermann G. Successful treatment of malignant placental site trophoblastic tumor with combined cytostatic-surgical approach: Case report and review of literature.  Gynecol Oncol. 1999;  75 164-169
    CrossrefPubMedGoogle Scholar
  • 36 Janni W, Hantschmann P, Rehbock J, Kindermann. Malignant placental site trophoblastic tumor - a rare gestational trophoblastic malignancy.  Geburtsh Frauenheilk. 2000;  60 302-307
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 37 Kaufmann P. Control of normal trophoblast invasion in the human placenta. Hauptmann S et al. Surgical Pathology Update. Berlin; ABW 2001: 161-165
    Google Scholar
  • 38 Kashimura Y, Kashimura M, Masamichi K, Sugimori H, Tsukamoto N, Matsuyama T, Matsukama K, Kamora T, Saito T, Kawano H, Nose R. Prophylactic chemotherapy for hydatidiform mole.  Cancer. 1986;  58 624-629
    PubMedGoogle Scholar
  • 39 Kendall Gollmore A R, Newlands E. Chemotherapy for trophoblastic disease: Current standards.  Curr Opin Obstet Gynecol. 2002;  14 33-38
    CrossrefPubMedGoogle Scholar
  • 40 Kim J H, Park D C, Bae S N, Namkoong S E, Kim S J. Subsequent reproductive experience after treatment for gestational trophoblastic disease.  Gynecol Oncol. 1998;  71 108-112
    CrossrefPubMedGoogle Scholar
  • 41 Kim S J, Bae S N, Kim J H, Kim C J, Han K T, Chung J K, Lee J M. Epidemiology and time trends of gestational trophoblastic disease in Korea.  Int J Gynaecol Obstet. 1998;  60 (Suppl 1) S33-38
    CrossrefPubMedGoogle Scholar
  • 42 Kohorn E I. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment.  Int J Gynecol Cancer. 2001;  11 73-77
    PubMedGoogle Scholar
  • 43 Klare P, Buchmann E. Erstmanifestation eines Chorionkarzinoms bei einer 24-jährigen Patientin in Form einer Hemiparese.  Zentralbl Gynäkol. 1997;  119 282-283
    PubMedGoogle Scholar
  • 44 Kurman R J, Scully R E, Norris H J. Trophoblastic pseudotumor of the uterus: An exaggerated form of “syncytial endometritis” simulating a malignant tumor.  Cancer. 1976;  38 1214-1226
    PubMedGoogle Scholar
  • 45 Kurman R J. The morphology, biology and pathology of the intermediate trophoblast: A look back to the present.  Hum Pathol. 1991;  22 847-855
    CrossrefPubMedGoogle Scholar
  • 46 Lan Z, Hongzaho S, Xiuyu Y, Yang X. Pregnancy outcomes of patients who conceived within 1 year after chemotherapy for gestational trophoblastic tumor: A clinical report of 22 patients.  Gynecol Oncol. 2001;  83 146-148
    CrossrefPubMedGoogle Scholar
  • 47 Lage J M, Bagg A, Berchem G J. Gestational trophoblastic disease.  Curr Opin Obstet Gynecol. 1996;  8 79-82
    PubMedGoogle Scholar
  • 48 Lage J M, Sheikh S S. Genetic aspects of gestational trophoblastic disease: A general overview with emphasis on new approaches in determining genetic composition.  Gen Diagn Pathol. 1997;  143 109-115
    PubMedGoogle Scholar
  • 49 Liotta L A, Rao C N, Wewer U M. Biochemical interactions of tumor cells with the basement membrane.  Am Rev Biochem. 1986;  55 1037-1057
    PubMedGoogle Scholar
  • 50 Lorigan P C, Sharma S, Bright N, Coleman R E, Hancock B W. Characteristics of women with recurrent molar pregnancies.  Gynecol Oncol. 2000;  78 288-292
    CrossrefPubMedGoogle Scholar
  • 51 Lurain J R. Treatment of gestational trophoblastic tumors.  Curr Treat Options Oncol. 2002;  3 113-124
    CrossrefPubMedGoogle Scholar
  • 52 Marchand F I. Ueber die sogenannten „decidualen“ Geschwülste im Anschluß an normale Geburt, Abort, Blasenmole und Extrauterinschwangerschaft.  Monatsschr Geburtsh Gynaekol. 1895;  1 513-563
    PubMedGoogle Scholar
  • 53 McNeish I A, Strickland S, Holden L, Rustin G J, Foskett M, Seckl M J, Newlands E S. Low-risk peristent gestational trophoblastic disaese: Outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.  J Clin Oncol. 2002;  20 1838-1844
    CrossrefPubMedGoogle Scholar
  • 54 Messerli M L, Parmley T, Woodruff J L, Lilienfeld A M, Bevilacqua L, Rosenheim N B. Inter- and intrapathologist variability in the diagnosis of gestational trophoblastic neoplasia.  Obstet Gynecol. 1987;  69 622-626
    PubMedGoogle Scholar
  • 55 Motzer R J, Cooper K, Geller N L, Bajorin R F, Dimitrovsky R, Herr H, Morse M, Fair W, Sogani P, Russo P. The role of ifosfamid and cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.  Cancer. 1990;  66 2476-2481
    PubMedGoogle Scholar
  • 56 Newlands E S, Mulholland P J, Holden L, Seckl M J, Rustin G J. Etoposide and cisplatin/etoposide, methotrexate and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients representing with metastatic placental site trophoblastic tumors.  J Clin Oncol. 2000;  18 854-859
    PubMedGoogle Scholar
  • 57 Ngan H YS, Odicino F, Maisonneuve P, Beller U, Benedt J L, Heintz A PM, Pecorelli S, Siderei M, Creasman W T. Gestational trophoblastic disease.  J Epidemiol Biostat. 2001;  6 177-184
    PubMedGoogle Scholar
  • 58 Olvera M, Harris S, Amezuca C A, McCourty A, Rezk S, Koo C, Felix J C, Brynes R K. Immunohistochemical expression of cell cycle proteins E2 F-1, Cdk-2, cyclin E, p27(kip 1) and Ki-67 in normal placenta and gestational trophoblastic disease.  Mod Pathol. 2001;  14 1036-1042
    CrossrefPubMedGoogle Scholar
  • 59 Papadopoulos A J, Foskett M, Seckl M J, McNeish I, Paradinas F J, Rees H, Newlands E S. Twenty-five year's clinical experience with placental site trophoblastic tumors.  J Reprod Med. 2002;  47 460-464
    PubMedGoogle Scholar
  • 60 Rice L W, Lage J M, Berkowitz R S, Goldstein D P, Bernstein M R. Repetitive complete and partial hydatidiform mole.  Obstet Gynecol. 1989;  74 217-219
    PubMedGoogle Scholar
  • 61 Ringertz N. Hydatidiform mole, invasive mole and choriocarcinoma in Sweden 1958 - 1965.  Acta Obstet Gynecol Scand. 1970;  49 195-203
    PubMedGoogle Scholar
  • 62 Rinne K, Shahabi S, Cole L. Following metastatic placental site trophoblastic tumor with urine β-core fragment.  Gynecol Oncol. 1999;  74 302-303
    CrossrefPubMedGoogle Scholar
  • 63 Roberts J P, Lurain J R. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy.  Am J Obstet Gynecol. 1996;  174 1917-1923
    PubMedGoogle Scholar
  • 64 Rutgers J L, Baergen R N, Young R H, Scully R E. Placental site trophoblastic tumor: Clinicopathologic study of 64 cases.  Mod Pathol. 1995;  8 96A
    PubMedGoogle Scholar
  • 65 Scully R E, Bonfiglio T A, Kurman R J, Silverberg S G, Wilkinson E J. WHO-Histological Typing of Female Genital Tract Tumours. Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, Barcelona, Budapest; Springer 1994
    Google Scholar
  • 66 Seckl M J, Fisher R A, Salerno G, Rees H, Paradinas F J, Foskett M, Newlands E S. Choriocarcinoma and partial hydatidiform moles.  Lancet. 2000;  356 1443-1444
    PubMedGoogle Scholar
  • 67 Seckl M J, Newlands E S. Treatment of gestational trophoblastic disease.  Gen Diagn Pathol. 1997;  143 159-171
    PubMedGoogle Scholar
  • 68 Shih I M, Kurman R J. Epitheloid trophoblastic tumor - a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma.  Am J Surg Pathol. 1998;  22 1393-1403
    CrossrefPubMedGoogle Scholar
  • 69 Shih I M, Kurman R J. The pathology of the intermediate trophoblastic tumors and tumorlike lesions.  Int J Gynecol Pathol. 2001;  20 31-47
    CrossrefPubMedGoogle Scholar
  • 70 Shih I M, Kurman R J. Molecular basis of gestational trophoblastic diseases.  Curr Mol Med. 2002;  2 1-12
    PubMedGoogle Scholar
  • 71 Shih I M, Seidman J D, Kurman R J. Placental site nodule and characterisation of distinctive types of intermediate trophoblast.  Hum Pathol. 1999;  30 687-694
    CrossrefPubMedGoogle Scholar
  • 72 Silverberg S G, Kurman R J. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. Atlas of Tumor Pathology. Washington, D. C.; Armed Forces Institute of Pathology 1992: 219-286
    Google Scholar
  • 73 Szulman A E. Syndromes of hydatidiform moles. Partial versus complete.  J Reprod Med. 1984;  29 788-791
    PubMedGoogle Scholar
  • 74 Vaccarello L, Apte S M, Diaz P T, Lewandowski G S, Copeland L J. Respiratory failure from metastatic choriocarcinoma: A survivor of mechanical ventilation.  Gynecol Oncol. 1997;  67 111-114
    CrossrefPubMedGoogle Scholar
  • 75 Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: Two entities. A morphologic and cytogenetic study with some clinical considerations.  Am J Obstet Gynecol. 1977;  127 167-170
    CrossrefPubMedGoogle Scholar
  • 76 Wallace D C, Surti U, Adams C W, Szulman A E. Complete moles have paternal chromosomes but maternal mitochondrial DNA.  Hum Genet. 1982;  61 145-147
    PubMedGoogle Scholar
  • 77 World Health Organisation Scientific Group on Gestational Trophoblastic Disease .Technical report Series No. 692. Geneva; WHO 1983
    Google Scholar
  • 78 Wittekind C, Meyer H J, Bootz F. TNM-Klassifikation maligner Tumoren. 6. Aufl. Berlin, Heidelberg, New York; Springer 2002
    Google Scholar
  • 79 Yang X, Zhang Z, Jia C, Li J, Yin L, Jiang S. The relationship between expression of c-ras, c-erbB-2, nm23 and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole.  Gynecol Oncol. 2002;  85 438-444
    CrossrefPubMedGoogle Scholar
  • 80 Yen S, MacMahon B. Epidemiologic features of trophoblastic disease.  Am J Obstet Gynecol. 1968;  101 126-132
    PubMedGoogle Scholar
  • 81 Young R H, Kurman R J, Scully R E. Placental site nodules and plaques: A clinicopathologic analysis of 20 cases.  Am J Surg Pathol. 1990;  14 1001-1009
    PubMedGoogle Scholar

OA PD Dr. med. L.-C. Horn

Institut für Pathologie
Universität Leipzig

Liebigstraße 26

04103 Leipzig

eMail: hornl@medizin.uni-leipzig.de